Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Orforglipron on Major Adverse Cardiovascular Events in ASCVD and/or CKD
jRCT2031250526Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD), heart failure (HF) and 2 more comparing Orforglipron arm with Placebo arm (2 arms). Primary endpoint: Time to first major adverse cardiovascular event. Started Dec 2025; status: recruiting.
02
Drugs
orforglipron
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)heart failure (HF)myocardial infarction (MI)stroke
Beyond the preview
Go deeper on jRCT2031250526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250526.